Tracey  Sacco net worth and biography

Tracey Sacco Biography and Net Worth

Chief Commercial Officer of Scholar Rock

Tracey Sacco has served as Chief Commercial Officer of Scholar Rock since February 2023. She is responsible for all commercial functions, including sales, marketing, market access, and commercial operations. Tracey has nearly two decades of biopharmaceutical industry experience, with much of her career focused on rare disease programs from early-stage development through launch. Prior to joining Scholar Rock, Ms. Sacco worked at The Nemetz Group, where she served as a strategic partner to biopharmaceutical companies on commercialization and corporate strategy. Previously, she held positions of increasing responsibility at Acceleron Pharma, most recently serving as Senior Vice President, Global Strategic Marketing. Prior to Acceleron, Ms. Sacco held roles in commercial strategy and business development at Sanofi (formerly Genzyme), Oscient Pharmaceuticals, and Pfizer. Ms. Sacco holds an MBA from NYU Stern School of Business and a B.A. in Economics and Sociology from Boston College. She is a member of the Life Science Cares Board of Advisors.    

What is Tracey Sacco's net worth?

The estimated net worth of Tracey Sacco is at least $3.24 million as of April 25th, 2025. Ms. Sacco owns 71,750 shares of Scholar Rock stock worth more than $3,243,100 as of December 4th. This net worth approximation does not reflect any other assets that Ms. Sacco may own. Additionally, Ms. Sacco receives an annual salary of $548,860.00 as Chief Commercial Officer at Scholar Rock. Learn More about Tracey Sacco's net worth.

How old is Tracey Sacco?

Ms. Sacco is currently 48 years old. There are 6 older executives and no younger executives at Scholar Rock. The oldest executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who is 69 years old. Learn More on Tracey Sacco's age.

What is Tracey Sacco's salary?

As the Chief Commercial Officer of Scholar Rock Holding Corporation, Ms. Sacco earns $548,860.00 per year. There are 3 executives that earn more than Ms. Sacco. The highest earning executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Tracey Sacco's salary.

How do I contact Tracey Sacco?

The corporate mailing address for Ms. Sacco and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Tracey Sacco's contact information.

Has Tracey Sacco been buying or selling shares of Scholar Rock?

Tracey Sacco has not been actively trading shares of Scholar Rock during the last ninety days. Most recently, Tracey Sacco sold 5,000 shares of the business's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $32.83, for a transaction totalling $164,150.00. Following the completion of the sale, the insider now directly owns 71,750 shares of the company's stock, valued at $2,355,552.50. Learn More on Tracey Sacco's trading history.

Who are Scholar Rock's active insiders?

Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.

Are insiders buying or selling shares of Scholar Rock?

In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.

Information on this page was last updated on 10/6/2025.

Tracey Sacco Insider Trading History at Scholar Rock

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/25/2025Sell5,000$32.83$164,150.0071,750View SEC Filing Icon  
3/24/2025Sell6,500$33.08$215,020.0071,750View SEC Filing Icon  
10/7/2024Sell30,000$25.62$768,600.0049,285View SEC Filing Icon  
See Full Table

Tracey Sacco Buying and Selling Activity at Scholar Rock

This chart shows Tracey Sacco's buying and selling at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scholar Rock Company Overview

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $45.20
Low: $42.83
High: $45.50

50 Day Range

MA: $34.97
Low: $27.92
High: $45.20

2 Week Range

Now: $45.20
Low: $22.71
High: $46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61